340B rebates will change how hospitals access savings on certain medications. Instead of receiving an upfront discount, covered entities would purchase selected drugs on their WAC account and submit eligible transaction data to receive a rebate afterward. 

For rural hospitals, preparing means understanding which medications may be affected, reviewing data workflows, and considering the potential impact on cash flow. Here is where things stand and what your team can begin evaluating. 

What Is Changing With 340B Rebates? 

The Health Resources and Services Administration (HRSA) has approved manufacturer plans under its revised 340B Rebate Model Pilot Program, with listed start dates of January 1, 2027. 

The pilot applies to selected drugs under approved plans. It does not replace upfront discounts for every 340B medication. Hospitals should review HRSA’s approved manufacturer plans to determine which products and covered entities are affected. 

How Does a 340B Rebate Model Work? 

The main difference is when the hospital receives financial benefits. 

With upfront 340B pricing, the discount is reflected in the purchase price. Under a rebate approach, the organization purchases the medication, submits the required transaction information, and receives a rebate after the claim is reviewed. 

HRSA describes verification of eligible transactions before payment as a central feature of the revised pilot. That makes accurate data and a reliable submission process important part of preparation. 

What Should Rural Hospitals Review Now? 

Preparing for a potential change requires coordination among pharmacy, finance, purchasing, and the hospital’s third-party administrator (TPA). A practical starting point is reviewing these four areas. 

1. Potentially Affected Medications 

Compare your organization’s medication purchasing and utilization with the products included in approved manufacturer plans. This can help your team estimate the potential impact rather than assuming every 340B purchase will change. 

2. Cash Flow and Reconciliation 

Evaluate the timing between purchasing a medication, submitting transaction data, and receiving payment. Consider how your team would track expected rebates, reconcile payments, and investigate outstanding amounts. 

These are planning considerations; the financial impact will depend on your organization’s purchasing volume, payment terms, and applicable rebate processes. 

3. Data Quality and Staff Responsibilities 

Identify where required information comes from and who will review it before submission. Discuss how pharmacy staff, your TPA, and other partners would coordinate corrections or resolve discrepancies. 

Clear ownership can help prevent important tasks from falling between departments. 

4. Manufacturer-Specific Instructions 

Use approved plans and current instructions to guide preparation. HRSA’s pilot requirements include provisions addressing submission platforms and advance notice to covered entities. Reviewing those materials will help your team understand the applicable process. 

Where Do Verification, Validation, and ESP Fit? 

As your team reviews rebate information, keep the requirements for each process clearly identified. 

Do not assume an existing ESP workflow satisfies a rebate submission requirement. Confirm which platform, instructions, and data requirements apply to each manufacturer and process before changing your procedures. 

Useful questions to discuss with your partners include: 

  • What information needs to be verified before submission? 
  • How will incomplete or inconsistent records be identified? 
  • Who will resolve rejected or disputed transactions? 
  • Which tasks belong to the hospital, TPA, or another partner? 

How Prairie Health Ventures Can Help

Managing change can be challenging when your pharmacy team already balances multiple responsibilities. 

Prairie Health Ventures provides 340B Program Management and 340B Align services for organizations seeking ongoing support or a focused program evaluation. Its services include assistance with manufacturer restrictions, TPA coordination, policies and procedures, reporting questions, and program analysis. 

If your hospital is evaluating what rebate developments could mean for its program, PHV can help you discuss your current operations and identify areas that may need closer review. 

Contact Prairie Health Ventures to discuss your organization’s 340B support needs. 

Frequently Asked Questions

Will every 340B drug move to a rebate model? 

No. HRSA’s revised pilot is limited to selected drugs covered by approved manufacturer plans. Other covered outpatient drugs without an approved rebate plan remain subject to upfront 340B pricing. 

When is the revised pilot expected to begin? 

HRSA currently lists January 1, 2027, starting date for approved plans. Because the program is being challenged, hospitals should verify the latest status before implementing changes. 

What is the first step in preparing? 

Start by identifying potentially affected medications and bringing pharmacy, finance, and your TPA together to review responsibilities, information needs, and payment tracking. 

Subscribe To Our Newsletter

Join our mailing list to receive the latest news and updates from our team.

You have Successfully Subscribed!